Download MendeleyVaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
Willis, J.R., Prabhakaran, M., Muthui, M., Naidoo, A., Sincomb, T., Wu, W., Cottrell, C.A., Landais, E., deCamp, A.C., Keshavarzi, N.R., Kalyuzhniy, O., Lee, J.H., Murungi, L.M., Ogonda, W.A., Yates, N.L., Corcoran, M.M., Phulera, S., Musando, J., Tsai, A., Lemire, G., Sein, Y., Muteti, M., Alamuri, P., Bohl, J.A., Holman, D., Himansu, S., Leav, B., Reuter, C., Lin, L.A., Ding, B., He, C., Straus, W.L., MacPhee, K.J., Regadas, I., Nyabundi, D.V., Chirchir, R., Anzala, O., Kimotho, J.N., Kibet, C., Greene, K., Gao, H., Beatman, E., Benson, K., Laddy, D., Brown, D.M., Bronson, R., Jean-Baptiste, J., Gajjala, S., Rikhtegaran-Tehrani, Z., Benner, A., Ramaswami, M., Lu, D., Alavi, N., Amirzehni, S., Kubitz, M., Tingle, R., Georgeson, E., Phelps, N., Adachi, Y., Liguori, A., Flynn, C., McKenney, K., Zhou, X., Owuor, D.C., Owuor, S.A., Kim, S.Y., Duff, M., Kim, J.Y., Gibson, G., Baboo, S., Diedrich, J., Schiffner, T., Shields, M., Matsoso, M., Santos, J., Syvertsen, K., Kennedy, A., Schroeter, M., Vekemans, J., Yates 3rd, J.R., Paulson, J.C., Hyrien, O., McDermott, A.B., Maenetje, P., Nyombayire, J., Karita, E., Ingabire, R., Edward, V., Muturi-Kioi, V., Maenza, J., Shapiro, A.E., McElrath, M.J., Edupuganti, S., Taylor, B.S., Diemert, D., Ozorowski, G., Koup, R.A., Montefiori, D., Ward, A.B., Karlsson Hedestam, G.B., Tomaras, G., Hunt, D.J., Muema, D., Sok, D., Laufer, D.S., Andrews, S.F., Nduati, E.W., Schief, W.R.(2025) Science 389: eadr8382-eadr8382
- PubMed: 40373112
- DOI: https://doi.org/10.1126/science.adr8382
- Primary Citation of Related Structures:
9MSD, 9MSY - PubMed Abstract:
A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI-G002 in the United States and IAVI-G003 in Rwanda and South Africa, we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI-G002). The vaccines were generally safe and well tolerated, except 18% of IAVI-G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM, and heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development. The results establish clinical proof of concept that heterologous boosting can advance bnAb-precursor maturation and demonstrate bnAb priming in Africa where the HIV burden is highest.
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Organizational Affiliation:
